Disease · MONDO_0005106
lipoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lipoma. Diseases, record MONDO_0005106. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005106
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- benign tumor of adipose tissue, benign tumour of adipose tissue, lipoma, benign, lipomatosis, familial multiple, lipomatous neoplasm, lipomatous neoplasm (morphologic abnormality), lipomatous tumor
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | CHEMBL2108709 | Enzyme | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEOXYCHOLIC ACID | CHEMBL406393 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UTENPANIUM CHLORIDE | CHEMBL5314928 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISOPROTERENOL | CHEMBL434 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor beta | 1 | Adrenergic receptor beta agonist | Phase 1/2 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 1 | Adrenergic receptor beta agonist | Phase 1/2 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta agonist | Phase 1/2 | https://conductscience.org/library/genes/155 | Drugs and targets |
| COL11A1 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/1301 | Drugs and targets |
| COL11A2 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/1302 | Drugs and targets |
| COL15A1 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/1306 | Drugs and targets |
| COL18A1 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/80781 | Drugs and targets |
| COL1A1 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/1277 | Drugs and targets |
| COL1A2 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/1278 | Drugs and targets |
| COL24A1 | Collagen | 1 | Collagen hydrolytic enzyme | Phase 2 | https://conductscience.org/library/genes/255631 | Drugs and targets |
1 to 10 of 29
See all 29 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00608842 | Phase 2 Study for the Treatment of Superficial Lipomas | Phase 2 | 62 | 2016-01-14 | Lipoma | DEOXYCHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT04229030 | RZL-012 for Dercum's Disease Lipomas | Phase 2 | 38 | 2024-02-07 | Dercum's Disease Lipomas | UTENPANIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02249052 | Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma | Phase 2 | 19 | 2016-12-13 | Lipoma | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | Its record names the disease | ClinicalTrials.gov |
| NCT01613313 | A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | Phase 2 | 14 | 2016-03-09 | Lipoma | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | Its record names the disease | ClinicalTrials.gov |
| NCT00624416 | Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas | Phase 1/2 | 10 | 2012-06-22 | Lipoma | ISOPROTERENOL, PREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT06820164 | Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride | Phase 1/2 | 20 | Lipoma | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| AA4500 vs Placebo: Responder Analysis | 17 of 19 | 0 of 19 | 38 | NCT02249052 | Trial comparisons |
| AA4500 vs Placebo: serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT02249052 | Trial comparisons |
| RZL-012 vs Vehicle of RZL-012: Exploratory | 0 of 20 | 0 of 18 | 38 | NCT04229030 | Trial comparisons |
| RZL-012 vs Vehicle of RZL-012: Safety Number of Participants With One or More Abnormal Laboratory Values up to Day 28 | 0 of 20 | 0 of 18 | 38 | NCT04229030 | Trial comparisons |
| RZL-012 vs Vehicle of RZL-012: deaths from any cause | 0 of 20 | 0 of 18 | 38 | NCT04229030 | Trial comparisons |
| RZL-012 vs Vehicle of RZL-012: serious adverse events | 0 of 20 | 0 of 18 | 38 | NCT04229030 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005106
GET https://conductscience.org/api/diseases/v1/MONDO_0005106/targets?page=2